文献速递其他结缔组织病类风湿关节炎

尼达尼布持续治疗对SARD-ILD相关PPF的获益:KEIO-SARD-ILD队列

Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort.
PubMed 文献 · Semin Arthritis Rheum · 2025-12-11

该研究基于KEIO-SARD-ILD队列65例接受尼达尼布治疗的SARD-ILD相关PPF患者,比较持续用药12个月与提前停药者的结局。持续组12个月%FVC变化为1.8%,停药组为-3.5%(p=0.01);KL-6变化分别为-175 U/mL与71 U/mL(p=0.04),持续组ILD相关生存率更优(p=0.02)。

要点

  • 持续尼达尼布12个月者%FVC较停药者改善(1.8% vs -3.5%,p=0.01)。
  • 持续组KL-6下降而停药组上升(-175 vs 71 U/mL,p=0.04)。
  • 持续组ILD相关生存率优于停药组(p=0.02)。

核心结论

  • 超过12个月持续尼达尼布治疗与SARD-ILD相关PPF患者肺功能、生物标志物及生存的显著改善相关,提示长期治疗可能起关键作用。

研究设计与样本

  • 基于KEIO-SARD-ILD队列,回顾2015至2025年所有连续接受尼达尼布治疗的SARD-ILD相关PPF患者,共65例。

主要发现

  • 65例中系统性硬化症最常见(n=16),其次为特发性炎性肌病(n=15)和类风湿关节炎(n=13)。
  • 尼达尼布总体12个月留存率为69.2%。
  • 用药前12个月,持续组与停药组%FVC下降程度相当(-3.6% vs -3.8%,p=0.58)。
  • 治疗12个月后,持续组%FVC改善显著优于停药组(1.8% vs -3.5%,p=0.01)。
  • 治疗12个月后,持续组KL-6变化显著优于停药组(-175 vs 71 U/mL,p=0.04);持续组ILD相关生存率优于停药组(p=0.02)。

关键数值与推荐

  • 主要结局为持续用药12个月组与提前停药组之间12个月预测用力肺活量百分比(%FVC)变化。
  • 次要结局包括两组12个月KL-6水平变化和死亡率。

临床怎么用

  • 在SARD-ILD相关PPF患者中,持续尼达尼布超过12个月与肺功能、KL-6及ILD相关生存的改善相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To clarify the real-world effectiveness of nintedanib continuation beyond 12 months on pulmonary function in progressive pulmonary fibrosis (PPF) associated with systemic autoimmune rheumatic disease-related interstitial lung disease (SARD-ILD). METHODS: We conducted a review of all consecutive SARD-ILD patients from the KEIO-SARD-ILD cohort who received nintedanib for PPF between 2015 and 2025. The primary outcome was the 12-month change in percent predicted forced vital capacity (%FVC) between patients who continued nintedanib for 12 months and those who discontinued treatment earlier. Secondary outcomes included 12-month changes in Krebs von den Lungen-6 (KL-6) levels and mortality between the two groups. RESULTS: Among the 65 patients, systemic sclerosis was the most common underlying condition (n = 16), followed by idiopathic inflammatory myopathies (n = 15), and rheumatoid arthritis (n = 13). The overall 12-month retention rate of nintedanib was 69.2 %. Both the continuation and discontinuation groups exhibited a comparable decline in %FVC in 12 months prior to nintedanib initiation (-3.6 % vs. -3.8 %, p = 0.58), but after 12 months of treatment, the continuation group demonstrated a significantly greater improvement in %FVC (1.8 % vs. -3.5 %, p = 0.01) and KL-6 (-175 vs 71 U/mL, p = 0.04) compared to the discontinuation group. The ILD-related survival rates were better in the continuation group compared to the discontinuation group (p = 0.02). CONCLUSIONS: Continuation of nintedanib beyond 12 months, compared with discontinuation within 12 months, is associated with significant improvements in pulmonary function, biomarkers, and survival in patients with SARD-ILD-related PPF, suggesting that long-term nintedanib therapy plays a critical role in stabilizing disease progression.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Suzuki K, Akiyama M, Shimanuki K, et al. Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort. Semin Arthritis Rheum. 2025. PMID: 41397362. doi:10.1016/j.semarthrit.2025.152891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。